Mutations of C-Reactive Protein (CRP) -286 SNP, APC and p53 in colorectal cancer: Implication for a CRP-Wnt crosstalk

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Su, Hai Xiang ^a,b   Zhou, Hai Hong ^a,b   Wang, Ming Yu ^c   Cheng, Jin ^c   Zhang, Shi Chao ^c   Hui, Feng ^c   Chen, Xue Zhong ^a,b   Liu, Shan Hui ^c   Liu, Qin Jiang ^a,b   Zhu, Zi Jiang ^a,b   Hu, Qing Rong ^a,b   Wu, Yi ^c   Ji, Shang Rong ^c  

^a Gansu Prov Elec Pwr Des Inst   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

^c LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; WNT PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CRP GENE; FEMALE; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOGENE; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSCRIPTION INITIATION SITE; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; COLORECTAL TUMOR; GENETICS; MUTATION; PROMOTER REGION;

C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; FEMALE; GENES, APC; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; WNT PROTEINS;

EID: 84904262147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102418     Document Type: Article

References (63)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
3. Ma X, Ji SR, Wu Y (2013) Regulated conformation changes in C-reactive protein orchestrate its role in atherogenesis. Chinese Sci Bull 58: 1642-1649.
4. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805-1812. (Pubitemid 38057722)
5. Allin KH, Nordestgaard BG (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48: 155-170.
6. Bottazzi B, Doni A, Garlanda C, Mantovani A (2010) An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 28: 157-183.
7. Du Clos TW (2013) Pentraxins: Structure, Function, and Role in Inflammation. ISRN Inflamm 2013: 379040.
8. Yang J, Wezeman M, Zhang X, Lin P, Wang M, et al. (2007) Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12: 252-265. (Pubitemid 47333419)
9. Kim ES, Cha Y, Ham M, Jung J, Kim SG, et al. (2013) Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPbeta and potentiates breast cancer progression. Oncogene.
10. Turu MM, Slevin M, Matou S, West D, Rodriguez C, et al. (2008) C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression. BMC Cell Biol 9: 47.
11. Mold C, Gewurz H, Du Clos TW (1999) Regulation of complement activation by C-reactive protein. Immunopharmacology 42: 23-30. (Pubitemid 29322284)
12. Gershov D, Kim S, Brot N, Elkon KB (2000) C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192: 1353-1364.
13. Singh SK, Suresh MV, Voleti B, Agrawal A (2008) The connection between C-reactive protein and atherosclerosis. Ann Med 40: 110-120. (Pubitemid 351640645)
14. Eisenhardt SU, Habersberger J, Peter K (2009) Monomeric C-reactive protein generation on activated platelets: the missing link between inflammation and atherothrombotic risk. Trends Cardiovasc Med 19: 232-237.
15. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE (2010) C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 102: 202-206.
16. Barna BP, James K, Deodhar SD (1987) Activation of human monocyte tumoricidal activity by C-reactive protein. Cancer Res 47: 3959-3963. (Pubitemid 17108453)
17. Barna BP, Deodhar SD, Gautam S, Yen-Lieberman B, Roberts D (1984) Macrophage activation and generation of tumoricidal activity by liposome-associated human C-reactive protein. Cancer Res 44: 305-310. (Pubitemid 14177755)
18. Deodhar SD, James K, Chiang T, Edinger M, Barna BP (1982) Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res 42: 5084-5088. (Pubitemid 13223151)
19. Wang MY, Zhou HH, Zhang SC, Hui F, Zhu W, et al. (2014) Recurrent mutations at C-reactive protein gene promoter SNP position -286 in human cancers. Cell Res 24: 505-508.
20. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, et al. (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897-1908.
21. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, et al. (2009) Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302: 37-48.
22. Armaghany T, Wilson JD, Chu Q, Mills G (2012) Genetic alterations in colorectal cancer. Gastrointest Cancer Res 5: 19-27.
23. Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6: 479-507.
24. Goel A, Boland CR (2010) Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol 26: 47-52.
25. Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
26. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, et al. (2004) C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109: 647-655. (Pubitemid 38198873)
27. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, et al. (2005) Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 102: 8309-8314. (Pubitemid 40800085)
28. Kovacs A, Tornvall P, Nilsson R, Tegner J, Hamsten A, et al. (2007) Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci U S A 104: 13768-13773. (Pubitemid 350003395)
29. Teupser D, Weber O, Rao TN, Sass K, Thiery J, et al. (2011) No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem 286: 6272-6279.
30. Carlucci F, Cook HT, Garg A, Pepys MB, Botto M (2010) Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. Arthritis Rheum 62: 245-249.
31. Rodriguez W, Mold C, Kataranovski M, Hutt J, Marnell LL, et al. (2005) Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 52: 642-650. (Pubitemid 40216331)
32. Hirschfield GM, Herbert J, Kahan MC, Pepys MB (2003) Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. J Immunol 171: 6046-6051. (Pubitemid 37467224)
33. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW (2002) C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 169: 7019-7025. (Pubitemid 36899289)
34. Koike T, Kitajima S, Yu Y, Nishijima K, Zhang J, et al. (2009) Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation 120: 2088-2094.
35. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, et al. (2005) Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 96: 714-716. (Pubitemid 40559509)
36. Lane T, Wassef N, Poole S, Mistry Y, Lachmann HJ, et al. (2014) Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res 114: 672-676.
37. Collaboration CRPCHDG, Wensley F, Gao P, Burgess S, Kaptoge S, et al. (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 342: d548.
38. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957-959.
39. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339: 959-961.
40. Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484-492.
41. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, et al. (2005) Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med (Berl) 83: 440-447. (Pubitemid 40922166)
42. Filep JG (2009) Platelets affect the structure and function of C-reactive protein. Circ Res 105: 109-111.
43. Schwedler SB, Filep JG, Galle J, Wanner C, Potempa LA (2006) C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis 47: 212-222. (Pubitemid 43121324)
44. Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, et al. (2007) Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J 21: 284-294. (Pubitemid 46052567)
45. Molins B, Pena E, de la Torre R, Badimon L (2011) Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovasc Res 92: 328-337.
46. Mihlan M, Blom AM, Kupreishvili K, Lauer N, Stelzner K, et al. (2011) Monomeric C-reactive protein modulates classic complement activation on necrotic cells. FASEB J 25: 4198-4210.
47. Hammond DJ, Jr., Singh SK, Thompson JA, Beeler BW, Rusinol AE, et al. (2010) Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem 285: 36235-36244.
48. Wang MY, Ji SR, Bai CJ, El Kebir D, Li HY, et al. (2011) A redox switch in C-reactive protein modulates activation of endothelial cells. FASEB J 25: 3186-3196.
49. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, et al. (2009) Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 105: 128-137.
50. Ji SR, Wu Y, Potempa LA, Qiu Q, Zhao J (2006) Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. Int J Biochem Cell Biol 38: 648-661. (Pubitemid 43117588)
51. Ji SR, Wu Y, Potempa LA, Liang YH, Zhao J (2006) Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 26: 935-941.
52. Xu PC, Li ZY, Yang XW, Zhao MH, Chen M (2014) Myeloperoxidase influences the complement regulatory function of modified C-reactive protein. Innate Immun 20: 440-448.
53. Yang XW, Tan Y, Yu F, Zhao MH (2012) Interference of antimodified C-reactive protein autoantibodies from lupus nephritis in the biofunctions of modified C-reactive protein. Hum Immunol 73: 156-163.
54. Skoglund C, Wettero J, Skogh T, Sjowall C, Tengvall P, et al. (2008) C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. Immunol Cell Biol 86: 466-474. (Pubitemid 351948221)
55. Khreiss T, Jozsef L, Potempa LA, Filep JG (2004) Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109: 2016-2022. (Pubitemid 38544493)
56. Khreiss T, Jozsef L, Potempa LA, Filep JG (2005) Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 97: 690-697. (Pubitemid 41416338)
57. Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, et al. (2008) C-Reactive Protein Isoforms Differ in Their Effects on Thrombus Growth. Arterioscler Thromb Vasc Biol 28: 2239-2246.
58. Ji SR, Ma L, Bai CJ, Shi JM, Li HY, et al. (2009) Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB J 23: 1806-1816.
59. Slevin M, Matou-Nasri S, Turu M, Luque A, Rovira N, et al. (2010) Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol 20: 151-165.
60. Boncler M, Rywaniak J, Szymanski J, Potempa LA, Rychlik B, et al. (2011) Modified C-reactive protein interacts with platelet glycoprotein Ibalpha. Pharmacol Rep 63: 464-475.
61. Li HY, Wang J, Wu YX, Zhang L, Liu ZP, et al. (2014) Topological localization of monomeric C-reactive protein determines pro-inflammatory endothelial cell responses. J Biol Chem 289: 14283-14290.
62. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149: 1192-1205.
63. Choi YS, Hur J, Jeong S (2007) Beta-catenin binds to the downstream region and regulates the expression C-reactive protein gene. Nucleic Acids Res 35: 5511-5519. (Pubitemid 47423924)